We are not currently shipping Fabrazyme.
Information about Fabrazyme (Agalsidase Beta)
Fabrazyme is an enzyme replacement therapy indicated for the treatment of Fabry disease, a rare genetic disorder resulting from the deficiency of the enzyme alpha-galactosidase A. Agalsidase beta is a recombinant form of this enzyme, designed to help manage the symptoms and complications associated with the disease.
Product Highlights
- Treatment of Fabry disease in adult and pediatric patients.
- Replenishes deficient enzyme to reduce substrate accumulation
Key Ingredient
Key Benefits
- Helps alleviate symptoms such as pain, gastrointestinal issues, and renal dysfunction.
- Slows the progression of Fabry disease-related complications.
- Enhances overall well-being for patients by addressing multiple manifestations of the disease.
Direction of Use
- Fabrazyme is administered via intravenous infusion.
- The recommended dosing schedule typically involves infusions every two weeks, but may vary based on individual patient needs.
- Monitoring for any adverse reactions during and after the infusion is essential.
Safety Concerns
- Common side effects may include infusion reactions, headache, and gastrointestinal symptoms.
- Patients should be monitored for allergic reactions or other severe side effects.
Avoid Fabrazyme (Agalsidase Beta) If
- You have a known hypersensitivity to agalsidase beta or any of its components.
- You have a severe infection or unstable medical condition without consulting a healthcare provider.
- You are pregnant or breastfeeding without discussing it with your healthcare provider.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
